CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers. Columbia researchers have now ...

A cancer drug class best known for attacking tumors may also help your immune system remember them better. Researchers at ...

A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.

B-cell lymphomas constitute a heterogeneous group of malignancies derived from B-lymphocytes, with diffuse large B-cell lymphoma (DLBCL) representing the most common subtype. Among these, double-hit ...